Targeted treatments for lung cancer
Monday 08 April 2019, Royal Marsden Hospital London
Description: In this course I describe the faulty genes, pathways and proteins that drive small cell and non-small cell lung cancer. I also explain the scientific rationale behind targeted treatments in use and in development for these diseases, including the progress made with checkpoint inhibitors such as nivolumab, pembrolizumab and durvalumab. Other treatments covered include inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, FGFR and Trk proteins, and angiogenesis inhibitors.
Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
To book, contact: email@example.com, or call: 020 7808 2922
Introduction to lung cancer: a disease of many layers
- Cell of origin of non-small cell and small cell lung cancer
- Mechanisms of development
- The molecular landscape of adenocarcinomas and squamous cell carcinomas
- The role of EGFR signalling pathways
- The immune system and lung cancer
Targeted treatments for non-small cell lung cancer – part 1
- EGFR sensitising mutations
- 1st, 2nd and 3rd generation EGFR-targeted treatments (gefitinib, erlotinib, afatinib, dacomitinib, neratinib, osimertinib)
- ALK inhibitors (crizotinib, ceritinib, alectinib,brigatinib, lorlatinib)
Immunotherapy approaches for lung cancer & current trials
- Introduction to T cells and checkpoint proteins
- Mechanism of action of checkpoint inhibitors (CTLA-4, PD-1 and PD-L1 monoclonal antibodies)
- Overview of the major clinical trials to date
- Biomarker development
Targeted treatments for non-small cell lung cancer – part 2
- Angiogenesis inhibitors
- More targets and treatments: B-Raf, HER2, MET, RET, NTRK
Targeted treatments for breast cancer
Thursday 25 May 2017, Christie Hospital Manchester
1-day course: Targeted Treatments for Breast Cancer
Description: This study day will describe many different faulty processes that drive the growth and spread of breast cancer. It will also introduce the science behind a plethora of licensed and yet-to-be licensed breast cancer treatments such as HER2-targeted therapies, PARP inhibitors and CDK inhibitors. To set the scene, the science behind standard treatments such as chemotherapy, radiotherapy and hormone therapy will be explained.
Audience: Ideal for research nurses, clinical nurse specialists, administrative staff, clinical trials coordinators
To book, contact: firstname.lastname@example.org or call: 0161 446 3403
Cancer cell biology & genetics – key concepts:
- Cells, DNA, chromosomes, genes, proteins
- Cell division & the cell cycle
- Causes, types and consequences of DNA damage
- Drivers of treatment resistance: the cancer microenvironment, genomic instability, intra-umoural heterogeneity
The cellular and molecular makeup of breast cancer
- How breast cancer develops
- Faulty genes and proteins that drive breast cancer
- The role of hormone receptors and HER2
- Breast cancer stem cells
- How and why breast cancers spread
The science behind cancer treatments
- The mechanism of action of chemotherapy and radiotherapy
- The history of hormone therapies for cancer
- Targeting cell communication pathways: monoclonal antibodies and kinase inhibitors
Targeted treatments for breast cancer
- The current landscape of breast cancer treatments
- Hormone therapies – targeting the oestrogen receptor and aromatase
- HER2-targeted treatments: trastuzumab, pertuzumab, lapatinib & T-DM1
- PI3K/AKT/mTOR pathway inhibitors e.g. everolimus , copanlisib, buparlisib
More targeted treatments for breast cancer
- BRCA genes & PARP inhibitors
- CDK inhibitors e.g. palbociclib
- New targets for triple-negative/basal-like breast cancer
- Immunotherapy for breast cancer
A beginner’s guide to immunotherapy
Wednesday 05 June 2019, Royal Marsden Hospital, London
Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
Description: In this half-day course (repeated Morning and afternoon) I describe the logic behind many immunotherapy-based cancer treatments such as checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab), adoptive cell transfer (CAR T cell therapy, infiltrating T cells), and vaccine-based treatments (peptide and DNA vaccines, oncolytic viruses, dendritic cell vaccines).
To book, contact: email@example.com or call: 020 7808 2922
The relationship between cancer and the immune system
- How cancer cells thrive alongside white blood cells
- The immune-suppressing cancer environment
Introduction to checkpoint inhibitors
- Checkpoint proteins on T cells
- Antibodies that target CTLA-4
- Antibodies that target PD-1 and PD-L1
- Successes so far: malignant melanoma, lung cancer, kidney cancer, Hodgkin lymphoma, head and neck cancer, bladder cancer
Introduction to adoptive cell transfer methods
- CAR T cell therapy for acute leukaemia and other cancers
- Infiltrating T cell therapy for malignant melanoma
Introduction to vaccine-based treatments
- Peptide- and DNA-based vaccines
- Oncolytic viruses including T-VEC
- Dendritic cell vaccines
- Where have we got to?
- Where are we going?
Promising Results for New Antibody Drug in Non-Small Cell Lung Cancer Patients
ECC 2013 Press Release: Promising Results for New Antibody Drug in Non-Small Cell Lung Cancer Patients: Smokers Respond Well | ESMO.
Today is the final day of the European Cancer Conference in Amsterdam. The organisers have released a stream of press releases to coincide with the conference, which you can browse here:
However I just wanted to pick out one, which describes recent results with one of a new group of antibody treatments that block the interaction between PD-L1 and PD-1.
As they explain in the press release:
“The programmed death 1 protein PD-1 and its signalling molecule (or ligand) PD-L1 prevent the body’s immune system from attacking and killing cancer cells and this allows the cancer to spread.
However, the anti-PD-L1 monoclonal antibody, MPDL3280A, works by blocking the interaction between PD-L1 and the immune system, thereby boosting a patient’s anti-cancer immune response.
The same news is covered on Medscape:
New Immunotherapy Could Be ‘Game Changer’ in NSCLC.
One of the most exciting aspects of the news is the discovery that benefits smokers and ex-smokers – people who are highly unlikely to have cancers that will respond to EGF-R inhibitors (Iressa & Tarceva) or ALK inhibitors (Zalkori).